✦ LIBER ✦

The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma

✍ Scribed by Kathleen M. Beusterien, Stacey J. Ackerman, Kathryn Plante, John Glaspy, Peter Naredi, Diana Wood, Kurt Gehlsen, Sanjiv S. Agarwala

Book ID: 113046541
Publisher: Springer-Verlag
Year: 2003
Tongue: English
Weight: 166 KB
Volume: 11
Category: Article
ISSN: 0941-4355
DOI: 10.1007/s00520-002-0419-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety profile of histamine dihydrochlor

Safety profile of histamine dihydrochloride administered with interleukin-2 in patients with advanced metastatic malignant melanoma

✍ S.J. O'Day; J. Glaspy; E. Whitman; C.L. Kass; K.R. Gehlsen; S.S. Agarwala 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 180 KB

The hematologic toxicity of interleukin-

The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma

✍ Mark P. Macfarlane; James C. Yang; Anshu S. Guleria; Richard L White Jr.; Claudi 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 744 KB

A Phase II study of “decrescendo” interl

A Phase II study of “decrescendo” interleukin-2 plus interferon-α-2a in patients with progressive metastatic melanoma after chemotherapy

✍ Omar Eton; Antonio C. Buzaid; Agop Y. Bedikian; Teresa M. Smith; Nicholas E. Pap 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

The authors tested a biotherapy regimen involving recombinant interferon-␣-2a (rIFN-␣-2a) and recombinant human interleukin-2 (rhIL-2), given in a "decrescendo" schedule over 5 days, for its activity and toxicity in 21 patients who previously had received chemotherapy for advanced melanoma. ## METH

A randomized study of neuroimmunotherapy

A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour

✍ P. Lissoni; S. Barni; V. Fossati; A. Ardizzoia; M. Cazzaniga; G. Tancini; F. Fri 📂 Article 📅 1995 🏛 Springer-Verlag 🌐 English ⚖ 334 KB

Health-related quality of life (HRQL) in

✍ D. Osoba; D. Slamon; M. Burchmore; M. Murphy 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 186 KB

The use of polyethylene glycol-modified

The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma

✍ James C. Yang; Suzanne L. Topalian; Douglas J. Schwartzentruber; David R. Parkin 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 707 KB